Abstract
Background Long COVID (LC) presents with complex pathophysiology, affecting multiple organs and producing a range of symptoms, from neuropsychiatric disturbances to multi-organ dysfunction. Liver damage has emerged as a notable feature, yet no systematic review or meta-analysis has comprehensively evaluated the biomarkers confirming liver injury in LC patients.
Objective The present study aims to examine blood-based biomarkers of liver damage in LC disease.
Methods A search of PubMed, Google Scholar, SciFinder, and SCOPUS identified 61 eligible studies, including 7172 participants, with 3404 LC patients and 3768 controls.
Results Our analysis identified a significant increase in the liver damage index among LC patients, with a moderate effect size (standardized mean difference, SMD = 0.553; confidence intervals; 95% CI: 0.305–0.760) compared to normal controls. Additionally, LC patients exhibited marked elevations in alanine aminotransferase (SMD = 0.615; 95% CI: 0.351;0.878), aspartate aminotransferase (SMD = 0.352; 95% CI: 0.068;0.637), gamma-glutamyl transferase (SMD = 0.969; 95% CI: 0.194;1.745), and lactate dehydrogenase (SMD = 0.666; 95% CI: 0.332;0.999) activities. Moreover, significant reductions were observed in total protein (SMD = -0.326; 95% CI: -0.631; -0.021) and increases in prothrombin time (SMD = 0.633; 95% CI: 0.077;1.189), ferritin (SMD = 0.437; 95% CI: 0.069;0.805), D-dimer (SMD = 0.359; 95% CI: 0.144;0.573). Further studies are needed to confirm reductions in platelet count and elevations in fibrinogen levels
Conclusion This study suggests that LC is associated with persistent liver damage and coagulopathy, highlighting the need to incorporate liver injury into treatment strategies to reduce potential risks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by FF66 grant and a Sompoch Endowment Fund (Faculty of Medicine), MDCU (RA66016) to MM, and Grant№BGRRP2.0040007С01Strategic Research and Innovation Program for the Development of MUPLOVDIV(SRIPDMUP),Creation of a network of research higher schools, National plan forrecovery and sustainability,European Union NextGenerationEU.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The corresponding author (MM) will address any reasonable requests for access to the dataset (Excel file) used in this meta-analysis,once all authors have fully utilized the data.
